NKp30 x TAA

The NKp30 bispecific engager platform originally developed for targeting BCMA is a highly modular format that can be extended to other tumor-targeting antibodies against hematological and solid tumor antigens. Using our common light chain discovery platform, Compass scientists have generated NKp30 bispecific engagers targeting diverse indications including NHL and breast cancer, with additional programs for prostate and ovarian cancer in progress. Our lead NKp30 x Her2 bispecific demonstrates enhanced activity compared to trastuzumab (Herceptin) targeting cells with a wide range of Her2 expression.